Screener
TG Therapeutics TGTX Other Non-Current Assets
Other Non-Current Assets at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Right of use assets | 7,085 | 6,278 |
| Deferred tax assets | 343,428 | 348,000 |
| Non-current inventories | 75,486 | 15,689 |
| Other noncurrent assets | 2,211 | 2,044 |
| Total assets | $1,639,629 | $1,063,253 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $213,693 | $107,508 |
Document
FAQ
- What is TG Therapeutics's other non-current assets?
- TG Therapeutics (TGTX) reported other non-current assets of $2.21M in Q2 2026.
- How has TG Therapeutics's other non-current assets changed year-over-year?
- TG Therapeutics's other non-current assets increased by 9.1% year-over-year, from $2.03M to $2.21M.
- What is the long-term trend for TG Therapeutics's other non-current assets?
- Over 2 years (2023 to 2025), TG Therapeutics's other non-current assets has grown at a -5.9% compound annual growth rate (CAGR), from $2.31M to $2.04M.
- What does other non-current assets mean?
- Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.
Ask your AI about TG Therapeutics's other non-current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude